MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics
Annals of Neurology · 2026-02 · 99 (2) · 449-458
DOI: 10.1002/ana.78040 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Annals of Neurology, online erschienen am 22.09.2025. Verfasst von Steven M Greenberg und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Cerebral Small Vessel Diseases, Cognitive Dysfunction. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Objective
To establish a framework for validating candidate biomarkers of cerebral small vessel diseases (SVD) associated with cognitive impairment and characterize individuals enrolled by the MarkVCID2 consortium under this framework.
Methods
Participants age 60 to 90 years were enrolled across 17 MarkVCID2 sites. Recruitment was targeted to enrich in cognitive symptoms (mild dementia, mild cognitive impairment, subjective cognitive decline), defined risk factors (diabetes mellitus, advanced hypertension), and Black/African American, White, and Hispanic/Latino subgroups. Enrolled participants underwent baseline visits that included cognitive testing, multimodal magnetic resonance imaging (MRI), and biofluid collection. Provisional risk for SVD‐related cognitive decline was estimated primarily by baseline cognitive symptoms plus SVD risk factors. Adjudicated risk status was estimated by cognitive symptoms plus presence of moderate‐to‐severe white matter hyperintensities, microbleeds, or lacunes on baseline MRI.
Results
MarkVCID2 enrolled 1883 individuals age 73.4 ± 7.5 years, 65.0% female, 24.2% Hispanic, and 27.1% non‐Hispanic Black. Among enrollees, 44.8% were provisionally designated high‐risk. After baseline MRI, 48.5% were categorized as adjudicated high‐risk status, with substantial recategorization both from low‐ to high‐risk (primarily because of MRI lesions without SVD risk factors) and high‐ to low‐risk (primarily suspected cognitive impairment at screening not confirmed by baseline testing).
Interpretation
MarkVCID2 baseline data indicate successful enrollment of diverse individuals enriched in factors associated with SVD‐related cognitive decline. Changes over 3 years of longitudinal follow‐up will be analyzed to validate the candidate biomarkers for 2 projected contexts of use: subject selection (identifying likelihood of future SVD progression) and study outcome (efficiently measuring SVD progression). ANN NEUROL 2026;99:449–458
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Mallinckrodt Institute of Radiology, Washington University in St Louis School of Medicine, St. Louis, MO, USA.
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA.
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
- Department of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, Chicago, IL, USA.
ORCID-Profile: Steven M Greenberg, Hongyu An, Konstantinos Arfanakis, Arnold M Evia, Arvind Caprihan, Andria L Ford, Myriam Fornage, Gregory S Day, Jason D Hinman, Gregory A Jicha, Amir H Kashani, Christian Lachner, Jin-Moo Lee, Peiying Liu, Hanzhang Lu, Pauline Maillard, Ronald C Petersen, Bruce M Psaty, John M Ringman, Gary A Rosenberg, Claudia L Satizabal, Sudha Seshadri, Prashanthi Vemuri, Danny J J Wang, Donna M Wilcock, Carissa Tuozzo, Herpreet Singh, Vilma Okey-Ewurum, Courtney B Page, Hillary Mulder, Pia Kivisäkk, Deborah Blacker, Lidiya Mazina, Karl G Helmer, Lisa M Wruck
Förderung
- NINDS NIH HHS
- NIA NIH HHS
Zitieren
APA
Greenberg, S. M., Albert, M. S., An, H., Arfanakis, K., Evia, A. M., Caprihan, A., Ford, A. L., Fornage, M., Day, G. S., Hinman, J. D., Jicha, G. A., Kashani, A. H., Kramer, J. H., Lachner, C., Lee, J. M., Liu, P., Lu, H., Maillard, P., Petersen, R. C., …, & MarkVCID2 Consortium (2026). MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics. Annals of Neurology, 99(2), 449-458. https://doi.org/10.1002/ana.78040
Vancouver
Greenberg SM, Albert MS, An H, Arfanakis K, Evia AM, Caprihan A, et al. MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics. Annals of Neurology. 2026;99(2):449-458. doi:10.1002/ana.78040
BibTeX
@article{Greenberg2026,
author = {Greenberg, Steven M and Albert, Marylin S and An, Hongyu and Arfanakis, Konstantinos and Evia, Arnold M and Caprihan, Arvind and Ford, Andria L and Fornage, Myriam and Day, Gregory S and Hinman, Jason D and Jicha, Gregory A and Kashani, Amir H and Kramer, Joel H and Lachner, Christian and Lee, Jin-Moo and Liu, Peiying and Lu, Hanzhang and Maillard, Pauline and Petersen, Ronald C and Psaty, Bruce M and Ringman, John M and Rosenberg, Gary A and Satizabal, Claudia L and Savitz, Sean I and Schneider, Julie A and Seshadri, Sudha and Vemuri, Prashanthi and Wang, Danny J J and Wilcock, Donna M and Windham, B Gwen and Zhang, Rong and Tuozzo, Carissa and Singh, Herpreet and Moy, Sue and Okey-Ewurum, Vilma and Page, Courtney B and Mulder, Hillary and Kivisäkk, Pia and Blacker, Deborah and Mazina, Lidiya and Helmer, Karl G and Schwab, Kristin and Wruck, Lisa M and Corriveau, Roderick A and MarkVCID2 Consortium, MarkVCID2 Consortium},
title = {MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics},
journal = {Annals of Neurology},
year = {2026},
volume = {99},
number = {2},
pages = {449--458},
doi = {10.1002/ana.78040}
}
EUVIMED